General autoimmunity

Oral

Literature Mining and Bioinformatics Analysis of Gene Expression Identifies Drug Targets for Treatment of Systemic Lupus Erythematosus (sle)

Friday, June 16
6:15 PM - 7:30 PM

Since new therapies for lupus have been extremely slow to develop and lupus patients have a great unmet medical need, an independent pharma-external effort has been undertaken to evaluate all FDA approved drugs for potential use in this autoimmune disease.  In 2013, literature mining evaluated the >1000 compounds approved by the FDA and identified 157 possible lupus therapies. These were ranked  using an evidence-based Composite Lupus Treatment Scoring (CoLTs) approach (Lupus 25:1150, 2016). Between 2014-2017, the FDA has approved 125 new drugs, seven of which targeted an autoimmune/inflammatory disease and none of which was approved for use in SLE. These drugs were evaluated for possible utility in autoimmune diseases and 43 were identified as possible therapies and ranked by the CoLT-scoring system. Nine were identified as high-priority candidates for repositioning into lupus including drugs targeting cellular metabolism, kinases and the immune system.  In addition, potential utility of drug candidates in SLE was gauged by bioinformatic analysis of gene expression profiles from lupus tissues (kidney, skin, synovium) and the periphery (Whole Blood, B cells, T cells, myeloid cells). Connectivity scoring with gene expression profiles available in the Library of Integrated Network Cellular Signatures (LINCS) confirmed many of the drug candidates and also suggested some unique potential drug therapies. The combination of literature mining and bioinformatic analysis of gene expression profiles has yielded a group of high priority candidates that have promise as therapies for SLE.

Amrie C. Grammer

COO & CSO
AMPEL BioSolutions, LLC

Presentation(s):

    Send Email for Amrie Grammer

    Matthew Ryals

    AMPEL BioSolutions

    Presentation(s):

      Send Email for Matthew Ryals

      Adam Labonte

      AMPEL BioSolutions

      Presentation(s):

        Send Email for Adam Labonte

        Sarah Heuer

        AMPEL BioSolutions

        Presentation(s):

          Send Email for Sarah Heuer

          Michelle D. Catalina

          AMPEL BioSolutions, LLC

          Presentation(s):

            Send Email for Michelle Catalina

            Peter Lipsky

            AMPEL BioSolutions

            Presentation(s):

              Send Email for Peter Lipsky


              Assets

              Literature Mining and Bioinformatics Analysis of Gene Expression Identifies Drug Targets for Treatment of Systemic Lupus Erythematosus (sle)



              Attendees who have favorited this

              Send Email for Literature Mining and Bioinformatics Analysis of Gene Expression Identifies Drug Targets for Treatment of Systemic Lupus Erythematosus (sle)